Herpes virus entry mediator (HVEM) is a newly discovered member of the tumor necrosis factor receptor (TNFR) superfamily that has a role in herpes simplex virus entry, in T cell activation and in tumor immunity. We generated mAb against HVEM and detected soluble HVEM (SHVEM) in the sera of patients with various autoimmune diseases. HVEM was constitutively expressed on CD4(+)and CD8(+)T cells, CD19(+)B cells, CD14(+)monocytes, neutrophils and dendritic cells. In three-way MLR, mAb 122 and 139 were agonists and mAb 108 had blocking activity. An ELISA was developed to detect sHVEM in patient sera. sHVEM levels were elevated in sera of patients with allergic asthma, atopic dermatitis and rheumatoid arthritis. The mAbs discussed here may be useful for studies of the role of HVEM in immune responses. Detection of soluble HVEM might have diagnostic and prognostic value in certain immunological disorders.
Animals ; Antibodies, Monoclonal/immunology ; Antibody Specificity ; Arthritis, Rheumatoid/blood/immunology ; Asthma/blood/immunology ; Autoimmune Diseases/*blood/immunology ; Cell Division ; Cell Line ; Dermatitis, Atopic/blood/immunology ; Female ; Flow Cytometry ; Humans ; Hypersensitivity/*blood/immunology ; Lymphocyte Culture Test, Mixed ; Mice ; Mice, Inbred BALB C ; Receptors, Tumor Necrosis Factor/*blood/immunology ; Receptors, Tumor Necrosis Factor, Member 14 ; Receptors, Virus/*blood/immunology ; Solubility